LA JOLLA, Calif., Sept. 8, 2011 /PRNewswire/ — Regulus Therapeutics
Inc., a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today
announced the presentation of recent advances in its microRNA
therapeutic preclinical programs for the treatment of metabolic
diseases and cancer. Specifically, Neil W. Gibson, Ph.D., Regulus’
chief scientific officer will provide updates on the company’s
programs targeting microRNA-33 and microRNA-21 at the 7th Annual
Meeting of the Oligonucleotide Therapeutics Society held Sept.
8–10, 2011, in Copenhagen, Denmark. In a talk titled
“Therapeutic Targeting of microRNAs,” Dr. Gibson will present new
data demonstrating that the inhibition of microRNA-33 with
proprietary oligonucleotide anti-miRs in animal models increased
levels of HDL-cholesterol (the ‘good’ cholesterol) and reduced
levels of triglycerides. Additional preclinical data
presented by Regulus confirmed that microRNA-21 is upregulated in
human cancers and that microRNA-21 inhibition impacts tumor burden
and significantly increases survival in preclinical models of
hepatocellular carcinoma.
“Our exciting data show that inhibiting dysregulated microRNAs
with our proprietary anti-miR oligonucleotides are effective at
altering disease pathogenesis in animal models and provide us
confidence to move these programs forward into clinical
development,” said Dr. Gibson. “Indeed, anti-miRs targeting miR-33
show promise as a novel strategy for treatment of cardiovascular
disease and metabolic syndrome while anti-miRs targeting miR-21
demonstrate robust efficacy in pre-clinical tumor models.”
Data updates will be made on the following programs:
miR-33. Regulus is developing microRNA therapeutics
targeting miR-33 using proprietary chemically modified anti-miR
oligonucleotides delivered systemically. microRNA-33a and b
(miR-33a/b), whi
‘/>”/>